MoonLake Immunotherapeutics (MLTX) Cash & Equivalents (2020 - 2026)

MoonLake Immunotherapeutics' Cash & Equivalents history runs 7 years deep, the most recent figure standing at $298.5 million for Q1 2026.

• On a quarterly basis, Cash & Equivalents rose 9.91% year-over-year to $298.5 million in Q1 2026; TTM through Mar 2026 was $298.5 million, a 9.91% increase from a year earlier, with the FY2025 full-year figure at $334.5 million, up 85.4% from the prior year.
• Cash & Equivalents fell to $298.5 million in Q1 2026 per MLTX's latest filing, from $334.5 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $501.8 million in Q2 2023 and bottomed at $23336.0 in Q1 2022.
• The 5-year median for Cash & Equivalents is $312.4 million (2023), against an average of $270.1 million.
• Across the five-year window, Cash & Equivalents tumbled 98.01% in 2022 and soared 214714.87% in 2023, its largest moves.
• Year by year, Cash & Equivalents stood at $39.5 million in 2022, then surged by 1042.04% to $451.2 million in 2023, then slumped by 60.01% to $180.4 million in 2024, then soared by 85.4% to $334.5 million in 2025, then slipped by 10.77% to $298.5 million in 2026.
• Per Business Quant, the three latest MLTX Cash & Equivalents figures stand at $298.5 million (Q1 2026), $334.5 million (Q4 2025), and $350.7 million (Q3 2025).